Follow
Julian Gillmore
Julian Gillmore
Verified email at ucl.ac.uk
Title
Cited by
Cited by
Year
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy, A Dispenzieri, ...
Circulation 133 (24), 2404-2412, 2016
18622016
CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis
JD Gillmore, E Gane, J Taubel, J Kao, M Fontana, ML Maitland, J Seitzer, ...
New England Journal of Medicine 385 (6), 493-502, 2021
12792021
Natural history and outcome in systemic AA amyloidosis
HJ Lachmann, HJB Goodman, JA Gilbertson, JR Gallimore, CA Sabin, ...
New England Journal of Medicine 356 (23), 2361-2371, 2007
12172007
Systemic amyloidosis
AD Wechalekar, JD Gillmore, PN Hawkins
The Lancet 387 (10038), 2641-2654, 2016
10582016
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
P Garcia-Pavia, C Rapezzi, Y Adler, M Arad, C Basso, A Brucato, ...
European heart journal 42 (16), 1554-1568, 2021
8262021
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis
HJ Lachmann, DR Booth, SE Booth, A Bybee, JA Gilbertson, JD Gillmore, ...
New England Journal of Medicine 346 (23), 1786-1791, 2002
7892002
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein
JD Gillmore, LB Lovat, MR Persey, MB Pepys, PN Hawkins
The Lancet 358 (9275), 24-29, 2001
7392001
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of …
S Dorbala, Y Ando, S Bokhari, A Dispenzieri, RH Falk, VA Ferrari, ...
Circulation: Cardiovascular Imaging 14 (7), e000029, 2021
731*2021
A new staging system for cardiac transthyretin amyloidosis
JD Gillmore, T Damy, M Fontana, M Hutchinson, HJ Lachmann, ...
European heart journal 39 (30), 2799-2806, 2018
6212018
Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis
M Fontana, S Pica, P Reant, A Abdel-Gadir, TA Treibel, SM Banypersad, ...
Circulation 132 (16), 1570-1579, 2015
6012015
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
A Jaccard, P Moreau, V Leblond, X Leleu, L Benboubker, O Hermine, ...
New England Journal of Medicine 357 (11), 1083-1093, 2007
5972007
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
HJ Lachmann, R Gallimore, JD Gillmore, HD Carr‐Smith, AR Bradwell, ...
British journal of haematology 122 (1), 78-84, 2003
5422003
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
AD Wechalekar, SO Schonland, E Kastritis, JD Gillmore, MA Dimopoulos, ...
Blood, The Journal of the American Society of Hematology 121 (17), 3420-3427, 2013
5342013
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
N Leung, F Bridoux, V Batuman, A Chaidos, P Cockwell, VD D’Agati, ...
Nature Reviews Nephrology 15 (1), 45-59, 2019
5242019
Native T1 mapping in transthyretin amyloidosis
M Fontana, SM Banypersad, TA Treibel, V Maestrini, DM Sado, SK White, ...
JACC: Cardiovascular Imaging 7 (2), 157-165, 2014
4702014
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
G Palladini, S Sachchithanantham, P Milani, J Gillmore, A Foli, ...
Blood, The Journal of the American Society of Hematology 126 (5), 612-615, 2015
4432015
Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis
T Lane, M Fontana, A Martinez-Naharro, CC Quarta, CJ Whelan, A Petrie, ...
Circulation 140 (1), 16-26, 2019
4302019
Senile systemic amyloidosis: clinical features at presentation and outcome
JH Pinney, CJ Whelan, A Petrie, J Dungu, SM Banypersad, ...
Journal of the American Heart Association 2 (2), e000098, 2013
4242013
T1 mapping and survival in systemic light-chain amyloidosis
SM Banypersad, M Fontana, V Maestrini, DM Sado, G Captur, A Petrie, ...
European heart journal 36 (4), 244-251, 2015
4202015
Therapeutic clearance of amyloid by antibodies to serum amyloid P component
DB Richards, LM Cookson, AC Berges, SV Barton, T Lane, JM Ritter, ...
New England Journal of Medicine 373 (12), 1106-1114, 2015
4132015
The system can't perform the operation now. Try again later.
Articles 1–20